Aardvark Therapeutics, Inc. Common Stock

Day range

$0.93 – $1.39

Open

$1.25

Prev close

$1.39

Volume

4.47M

Market cap

$30.42M

Shares out

21.88M

P/E

—

P/S

—

P/B

0.41

P/FCF

—

ROE

-93.4%

ROA

-85.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 23, 2026

  On October 23, 2026, Aardvark Therapeutics, Inc. (the "Company") issued a press release reporting exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective ("HERO") trial and open-label extension ("OLE") trial.

• Regulatory decisionOct 22, 2026

  On October 22, 2026, Aardvark Therapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration lifted the clinical hold on the Company's Investigational New Drug application for ARD-101 for the treatment of hyperphagia in Prader-Willi Syndrome.

• Executive compensation changeOct 8, 2026

  In accordance with the Company's Non-Employee Director Compensation Program (the "Program"), as a non-employee director of the Company, Dr. Zhang is entitled to receive cash compensation in the amount of $40,000 per year for his service on the Board... on October 7, 2026, Dr. Zhang was granted an option with respect to such number of shares of the Company's common stock as is equal to $500,000, divided by the per share grant date fair value of the option award (the "Appointment Option").

• New auditor engagementAug 17, 2026

  To ratify the appointment by the Audit Committee of the Company's Board of Directors of BDO USA, P.C. as the independent registered public accounting firm and independent auditor of the Company for the year ending December 31, 2026. As a result, the Company's stockholders voted to ratify the appointment by the Audit Committee of the Company's Board of Directors of BDO USA, P.C.

• Executive compensation changeJun 12, 2026

  On June 10, 2026, the Company also entered into a retention bonus letter agreement with Manasi Jaiman, M.D., M.P.H., the Company's Chief Medical Officer... Dr. Jaiman will, subject to the satisfaction of the conditions set forth therein, be entitled to receive a cash retention bonus in the aggregate amount of $357,000 (the "Jaiman Retention Bonus"), comprised of (i) a guaranteed annual bonus for 2026 of $204,000 and (ii) a retention bonus of $153,000.

Days to cover

5.3

Short interest

474.08K

Avg volume

89.63K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
  neutralGlobeNewswire Inc.· Oct 23, 2026
• All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
  positiveZacks Investment Research· Oct 21, 2026
• AARD DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important October 13 Deadline in Securities Class Action – AARD
  negativeGlobeNewswire Inc.· Oct 11, 2026
• AARD 截止日期通知：知名律師事務所 ROSEN 提醒 Aardvark Therapeutics, Inc. 投資人，應於證券集體訴訟重要期限 10 月 13 日之前委任法律律師 – AARD
  negativeGlobeNewswire Inc.· Oct 11, 2026
• URGENT AARDVARK DEADLINE: Bragar Eagel & Squire, P.C. Urges Aardvark Therapeutics, Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 13th
  negativeGlobeNewswire Inc.· Oct 10, 2026